| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Human Endogenous Metabolite
|
|---|---|
| References | |
| Additional Infomation |
Alanine is an α-amino acid formed by introducing an amino substituent at the 2-position of propionic acid. It is an important metabolite functionally related to propionic acid. It is the conjugate base and conjugate acid of alanine salts, and also a tautomer of alanine zwitterions. Alanine is a non-essential amino acid, existing in high concentrations in its free state in blood plasma. It is produced from pyruvate via transamination. It participates in the metabolism of sugars and acids, enhances immunity, and provides energy for muscle tissue, the brain, and the central nervous system. DL-alanine has been reported to exist in fruit flies, European aspen, and other organisms with relevant data. Alanine is an essential small-molecule amino acid for humans and one of the most commonly used amino acids in protein synthesis, participating in the metabolism of tryptophan and vitamin pyridoxine. Alanine is an important energy source for muscles and the central nervous system, enhances the immune system, aids in the metabolism of sugars and organic acids, and has a cholesterol-lowering effect in animals. (NCI04) DL-alanine is a racemic mixture of alanine (a non-essential α-amino acid). Alanine is one of the most common amino acid residues in protein synthesis, participating in the metabolism of tryptophan and vitamin pyridoxine. Furthermore, alanine is an important energy source for muscles and the central nervous system. It enhances the immune system, aids in the metabolism of carbohydrates and organic acids, and has a cholesterol-lowering effect in animals. Alanine is a non-essential amino acid, existing in large quantities in the plasma in a free state. It is produced from pyruvate via transamination. Alanine participates in the metabolism of carbohydrates and acids, enhances immunity, and provides energy for muscle tissue, the brain, and the central nervous system. See also: alanine (note moved to); D-alanine (note moved to). Pharmaceutical Indications For protein synthesis. Mechanism of Action L-alanine is a non-essential amino acid, existing in large quantities in the plasma in a free state. It is produced from pyruvate via transamination. It participates in the metabolism of carbohydrates and acids, enhances immunity, and provides energy for muscle tissue, the brain, and the central nervous system. Branched-chain amino acids (BCAAs) are the energy source for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscle. Their carbon skeleton is used as fuel, while their nitrogenous portion is used to synthesize another amino acid—alanine. Alanine is then converted into glucose in the liver. This energy production pathway is known as the alanine-glucose cycle, and it plays a crucial role in maintaining blood sugar balance in the body.
|
| Molecular Formula |
C3H7NO2
|
|---|---|
| Molecular Weight |
89.09
|
| Exact Mass |
89.047
|
| CAS # |
302-72-7
|
| Related CAS # |
D-Alanine;338-69-2;L-Alanine;56-41-7;DL-Alanine-13C-1;102029-81-2;DL-Alanine-13C-3;131157-42-1;DL-Alanine-d3;53795-94-1;DL-Alanine-15N;71261-64-8
|
| PubChem CID |
602
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
212.9±23.0 °C at 760 mmHg
|
| Melting Point |
272-275ºC
|
| Flash Point |
82.6±22.6 °C
|
| Vapour Pressure |
0.1±0.9 mmHg at 25°C
|
| Index of Refraction |
1.460
|
| LogP |
-0.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
6
|
| Complexity |
61.8
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QNAYBMKLOCPYGJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)
|
| Chemical Name |
2-aminopropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL (561.23 mM)
DMSO: < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 11.2246 mL | 56.1230 mL | 112.2460 mL | |
| 5 mM | 2.2449 mL | 11.2246 mL | 22.4492 mL | |
| 10 mM | 1.1225 mL | 5.6123 mL | 11.2246 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.